Table 4.
Knowledge of Czech HCWs responding to the HMPXV survey, September 2022 (n = 341).
| Variable | Outcome | HMPXV Vaccine Rejection (n = 153) |
HMPXV Vaccine Hesitancy (n = 158) |
HMPXV Vaccine Acceptance (n = 30) |
Total (n = 341) |
p |
|---|---|---|---|---|---|---|
| Perceived Knowledge | Epidemiology: (1–5) | 2.7 ± 0.9 | 2.9 ± 0.9 | 2.9 ± 1.0 | 2.8 ± 1.0 | 0.053 |
| Clinical presentation: (1–5) | 3.0 ± 1.0 | 3.1 ± 1.0 | 3.2 ± 1.0 | 3.1 ± 1.0 | 0.250 | |
| Risk factors: (1–5) | 3.2 ± 1.0 | 3.3 ± 0.9 | 3.4 ± 0.9 | 3.2 ± 1.0 | 0.532 | |
| Vaccination: (1–5) | 2.6 ± 1.0 | 2.8 ± 0.9 | 2.8 ± 1.0 | 2.7 ± 1.0 | 0.316 | |
| Treatment: (1–5) | 2.7 ± 1.0 | 2.9 ± 0.9 | 2.8 ± 1.1 | 2.8 ± 1.0 | 0.094 | |
| Factual Knowledge: Epidemiology | Incubation period | 95 (62.1%) | 90 (57.0%) | 18 (60.0%) | 203 (59.5%) | 0.653 |
| Case–fatality ratio | 76 (49.7%) | 76 (48.1%) | 20 (66.7%) | 172 (50.4%) | 0.170 | |
| Endemic region | 99 (64.7%) | 89 (56.3%) | 16 (53.3%) | 204 (59.8%) | 0.241 | |
| Total (0–3) | 1.8 ± 1.1 | 1.6 ± 1.1 | 1.8 ± 1.2 | 1.7 ± 1.1 | 0.425 | |
| Factual Knowledge: Clinical Presentation | Clinical symptoms | 135 (88.2%) | 138 (87.3%) | 29 (96.7%) | 302 (88.6%) | 0.387 |
| Differential diagnosis | 62 (40.5%) | 59 (37.3%) | 17 (56.7%) | 138 (40.5%) | 0.142 | |
| Lesions’ locations | 118 (77.1%) | 119 (75.3%) | 25 (83.3%) | 262 (76.8%) | 0.630 | |
| Total (0–5) | 3.0 ± 1.5 | 3.0 ± 1.6 | 3.7 ± 1.4 | 3.0 ± 1.6 | 0.047 | |
| Factual Knowledge: Risk Factors | Transmission pathways | 127 (83.0%) | 131 (82.9%) | 28 (93.3%) | 286 (83.9%) | 0.372 |
| Vertical transmission | 34 (22.2%) | 33 (20.9%) | 13 (43.3%) | 80 (23.5%) | 0.026 | |
| Sexual transmission | 109 (71.2%) | 101 (63.9%) | 25 (83.3%) | 235 (68.9%) | 0.077 | |
| Total (0–4) | 2.3 ± 1.1 | 2.2 ± 1.2 | 2.8 ± 1.0 | 2.3 ± 1.2 | 0.014 | |
| Factual Knowledge: Vaccination | Vaccine availability | 54 (35.3%) | 44 (27.8%) | 17 (56.7%) | 115 (33.7%) | 0.008 |
| Pre-exposure prophylaxis | 88 (57.5%) | 95 (60.1%) | 20 (66.7%) | 203 (59.5%) | 0.633 | |
| Cross-immunisation | 58 (37.9%) | 59 (37.3%) | 15 (50.0%) | 132 (38.7%) | 0.411 | |
| Total (0–4) | 1.5 ± 1.2 | 1.5 ± 1.3 | 2.1 ± 1.2 | 1.5 ± 1.2 | 0.031 | |
| Factual Knowledge: Treatment | Treatment availability | 36 (23.5%) | 43 (27.2%) | 7 (23.3%) | 86 (25.2%) | 0.733 |
| Medications listed | 18 (11.8%) | 27 (17.1%) | 6 (20.0%) | 51 (15.0%) | 0.257 | |
| Prognosis | 75 (49.0%) | 75 (47.5%) | 15 (50.0%) | 165 (48.4%) | 0.947 | |
| Total (0–4) | 0.9 ± 0.9 | 0.9 ± 0.9 | 0.9 ± 0.7 | 0.9 ± 0.9 | 0.640 |
The chi-squared (χ2) test, Fisher’s exact test, and the Kruskal–Wallis (H) test were used with a significance level (p) of ≤0.05.